JPMorgan’s analysis shows biopharma dealmaking surged in Q1 2026, driven mainly by licensing and M&A even as venture capital stayed cautious toward early-stage risk. The report cited licensing partnerships reaching $82.7 billion in announced value during Q1, while upfront cash represented about 6% of total deal value—indicating milestone-heavy back-end economics. M&A totaled $40.9 billion across 32 deals, with strategic buyers focusing on pipeline replenishment and later-stage assets. The analysis also highlighted a widening gap between early and late-stage capital allocation as venture funding totaled $6.9 billion in Q1 2026, down from $8.6 billion a year earlier. The net effect is a market that remains active for externally validated assets, but where seed and Series A financing continues to lag.